Worldquant Millennium Quantitative Strategies LLC raised its holdings in Eli Lilly And Co (NYSE:LLY) by 31.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 143,502 shares of the company’s stock after acquiring an additional 34,258 shares during the period. Worldquant Millennium Quantitative Strategies LLC’s holdings in Eli Lilly And Co were worth $16,606,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Athena Capital Advisors LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter worth approximately $26,000. Larson Financial Group LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter worth approximately $29,000. Ironwood Financial llc purchased a new position in shares of Eli Lilly And Co during the 4th quarter worth approximately $30,000. Acima Private Wealth LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter worth approximately $33,000. Finally, Essex Investment Management Co. LLC purchased a new position in shares of Eli Lilly And Co during the 4th quarter worth approximately $34,000. Institutional investors own 79.59% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $122.48, for a total value of $25,108,400.00. Following the completion of the transaction, the insider now owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the business’s stock in a transaction that occurred on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 834,190 shares of company stock valued at $102,516,602. Company insiders own 0.11% of the company’s stock.

Shares of NYSE:LLY traded down $0.57 during trading on Wednesday, reaching $130.45. The stock had a trading volume of 1,085,983 shares, compared to its average volume of 36,146,436. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. The firm has a market cap of $134.52 billion, a PE ratio of 23.50, a P/E/G ratio of 2.46 and a beta of 0.33. Eli Lilly And Co has a fifty-two week low of $75.14 and a fifty-two week high of $132.13.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). The firm had revenue of $6.44 billion during the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. As a group, sell-side analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on LLY shares. Zacks Investment Research upgraded shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 price objective on the stock in a report on Wednesday, December 19th. Credit Suisse Group set a $121.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, March 22nd. UBS Group assumed coverage on shares of Eli Lilly And Co in a research report on Wednesday, March 20th. They set a “buy” rating and a $74.51 price objective on the stock. Bank of America set a $129.00 price objective on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Finally, JPMorgan Chase & Co. assumed coverage on shares of Eli Lilly And Co in a research report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 price objective on the stock. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average price target of $115.68.

COPYRIGHT VIOLATION WARNING: “Worldquant Millennium Quantitative Strategies LLC Acquires 34,258 Shares of Eli Lilly And Co (LLY)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/worldquant-millennium-quantitative-strategies-llc-acquires-34258-shares-of-eli-lilly-and-co-lly/2921735.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: How does a 12b-1 fee affect fund performance?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.